About Perseus Holdings

About company

Perseus Holdings is an immuno-oncology company that is focused on the development and commercialization of immune-mediated technologies for the treatment of cancer. The company holds executive licenses for the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine, and the tumor lysate, particle only (TLPO) vaccine – both personalized therapeutic cancer vaccines designed to attack cancer cells by igniting innate and adaptive immune responses which increase a patient's own production of T cells to fight their specific cancer.